
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>



































| Assay Type | FACS |
| Analyte | IL-6 |
| Format | 50 tests×2 |
| Reactivity | Mouse |
| Regulatory Status | RUO |
| Sensitivity | 2.37 pg/mL |
| Standard Curve Range | 9.8-10000pg/mL |
| Assay Time | 2.5 hr |
| Suitable Sample Type | Mouse serum |
| Sample volume | 30 μL |
We offer a range of individual reagents for each factor, giving you the flexibility to select and combine them according to your specific research requirements.
This Panel (Flow Cytometry Bead Assay) gives quantitative results of Interleukin-6 (IL-6) with a sample testing. The performance of this panel has been optimized for specific analysis of cytokines.
It is for research use only.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The shelf life is 30 days from the date of opening.
| ID | Components | Size |
| FMBc004-02 | Anti-mouse IL-6 Antibody-coupled APC-beads-B04 | 50 tests |
| FABr016-B | Biotinylated Monoclonal Anti-Mouse IL-6 Antibody, Rat IgG2a (AS543) | 0.25 mL |

A double logarithmic fitting curve was plotted for IL-6. The present curve of each cytokines was ranging from 9.8 pg/mL to 10000 pg/mL.

A representative scatter plot showing single bead population in P1 gate (left), the beads conjugated with analyte-sepcific antibody differntiated by APC fluorescence intensity (middle), and fluorescence signal in propotion to concentration of the analyte was measured for each cytokine in PE channel (right). Data was generated on BD FACSymphony™ A1 Flow Cytometer, equipped with blue laser (561 nm) and red laser (637 nm).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Luminol sodium | MP-1032 | Approved | Selvim, Metrio | Psoriasis; Immune System Diseases | null | 1997-01-01 | Immune System Diseases; Psoriasis | Details | ||
| Siltuximab | cCLB-8; CNTO-328 | Approved | Johnson & Johnson | Sylvant | Mainland China | Multicentric Castleman's Disease (MCD) | Beigene (Beijing) Biotechnology Co Ltd | 2014-04-23 | Immunoglobulin Light-chain Amyloidosis; Leukemia, Large Granular Lymphocytic; Thrombocytopenia; Lymphoma, Non-Hodgkin; Lung Neoplasms; Primary Myelofibrosis; Colorectal Neoplasms; Castleman Disease; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Prostatic Neoplasms; Multicentric Castleman's Disease (MCD); Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Kidney Neoplasms; Myelodysplastic Syndromes; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Psychotic Disorders; Polycythemia Vera; Carcinoma, Renal Cell; Schizophrenia; Diabetes Mellitus, Type 1; Cytokine Release Syndrome; Head and Neck Neoplasms; Ovarian Neoplasms; Bone Marrow Neoplasms | Details |
| Pomalidomide | IMID-4047; CDC-394; CC-4047; IMiD-1 | Approved | Celgene Corp | Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 | Mainland China | Multiple Myeloma | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2013-02-08 | Pulmonary Fibrosis; Anemia, Sickle Cell; Atypical Squamous Cells of the Cervix; Neurofibromatosis 1; Sarcoma, Kaposi; Lymphoma, Non-Hodgkin; Carcinoma, Small Cell; Glioma; Waldenstrom Macroglobulinemia; Primary Myelofibrosis; Sarcoma; Prostatic Neoplasms; Thrombocytosis; Lung Diseases, Interstitial; Solid tumours; Central Nervous System Neoplasms; Multiple Myeloma; Hodgkin Disease; Scleroderma, Systemic; Pancreatic Neoplasms; Kidney Diseases; Immunoglobulin Light-chain Amyloidosis; Graft vs Host Disease; Myeloproliferative Disorders; Plasmacytoma; Polycythemia Vera; Medulloblastoma; Bone Marrow Neoplasms | Details |
| Lenalidomide | CC-5013; IMiD-3; ENMD-0997; STAR-LLD; CDC-501; IMID-5013; CDC-5013 | Approved | Celgene Corp | Revimid (former Brand Name), 瑞复美, Revlimid, Leavdo | EU | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular | Celgene Europe Bv | 2005-12-27 | Leukemia; Leukemia, Myeloid; Immunoproliferative Small Intestinal Disease; Leukemia, Erythroblastic, Acute; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell, Marginal Zone; Ovarian Neoplasms; Medulloblastoma; Intestinal Neoplasms; Bone Marrow Neoplasms; Solid tumours; Kidney Neoplasms; Liver Neoplasms; HIV Infections; Hematologic Diseases; Optic Nerve Glioma; Leukemia, Promyelocytic, Acute; Ependymoma; Anemia, Refractory, with Excess of Blasts; Plaque, Amyloid; Leukemia, Hairy Cell; Anemia; Paraproteinemias; Pain; Polycythemia Vera; Rhabdoid Tumor; Hodgkin Disease; Myelodysplastic Syndromes; Nerve Degeneration; Lymphomatoid Granulomatosis; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Anemia, Refractory; Leukemia-Lymphoma, Adult T-Cell; Plasmacytoma; Lymphoma, Large B-Cell, Diffuse; Blood Protein Disorders; Neoplasms; Glioblastoma; Leukemia, Myelomonocytic, Chronic; Graft vs Host Disease; Hypothalamic Neoplasms; Myeloproliferative Disorders; Leukemia, Myelomonocytic, Acute; Urinary Bladder Neoplasms; Multi | Details |
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | Osteosarcoma; Leprosy, Lepromatous; Drug Resistant Epilepsy; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Waldenstrom Macroglobulinemia; Cholangitis, Sclerosing; HIV Wasting Syndrome; Arachnoiditis; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Pancreatitis, Chronic; Lymphoma, Follicular; Sarcoma; Xerostomia; Burning Mouth Syndrome; Neoplasm Metastasis; Mycobacterium avium-intracellulare Infection; Vascular Malformations; Amyotrophic Lateral Sclerosis; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Erythema Nodosum; Anemia, Sideroblastic; Uterine Neoplasms; Lymphoma, Non-Hodgkin; Glioma; Angiodysplasia; Pelvic Pain; Appendiceal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Mycobacterium Infections; Gastric Antral Vascular Ectasia; Carcinoid Tumor; Lupus Erythematosus, Discoid; Stomatitis, Aphthous; Rhabdomyosarcoma; | Details |
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Anti-interleukin-6 receptor monoclonal antibody (Biocad) | Phase 2 Clinical | Biocad | Autoimmune Diseases | Details | |
| Wogonin | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University | Respiratory Tract Infections; Neoplasms | Details | |
| Mycobacterium cell wall-DNA Complex (ProMetic Life Sciences) | EN-3348 | Prometic Life Sciences | Details | ||
| MEDI-5117 | WBP-216; MEDI-5117 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Medimmune | Arthritis, Rheumatoid | Details |
| PF-04236921 | PF-4236921; PF-04236921 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
| Olokizumab | CDP-6038; Anti-IL6-UCB | Ucb | Details | ||
| Ensereptide | PXL-01 | Phase 3 Clinical | Promore Pharma | Post-surgical adhesions; Cicatrix | Details |
| FB-704A | FB-704; FB-704A | Phase 2 Clinical | Fountain Biopharma Inc | Arthritis, Rheumatoid; Asthma | Details |
| Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Depression; Anxiety; Hashimoto Disease; Coronavirus Disease 2019 (COVID-19); Healthy Aging; Inflammation | Details |
| Sirukumab | BA-003; CNTO-136 | Phase 2 Clinical | Glaxosmithkline Plc, Janssen Global Services Llc | Giant Cell Arteritis; Depressive Disorder, Major; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Lupus Erythematosus, Cutaneous; Lupus Nephritis; Polymyalgia Rheumatica; Lupus Erythematosus, Systemic; Asthma | Details |
| Monoclonal Antibody (Mab) sB24M | Phase 1 Clinical | Swiss Biopharma Med GmbH | Pyoderma Gangrenosum; Pyoderma | Details | |
| Efprezimod alfa | CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 | Phase 3 Clinical | Oncoimmune Inc | Leukemia; Hematopoietic stem cell transplantation (HSCT); HIV Infections; Solid tumours; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dyslipidemias; Leukemia, Myeloid, Acute; Melanoma | Details |
| Clazakizumab | ALD-518; ALD518-003; BMS-645429; BMS-945429 | Phase 3 Clinical | Alder Biopharmaceuticals | Plaque, Atherosclerotic; Arthritis, Rheumatoid; Fatigue; Coronavirus Disease 2019 (COVID-19); Graft vs Host Disease; Rejection of organ transplantation; Arthritis, Psoriatic; Asthma; Cachexia; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Stomatitis; Kidney Failure, Chronic | Details |
| RO-7200220 | RO-7200220 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Diabetic macular oedema | Details |
| Tocilizumab biosimilar (Mycenax Biotech) | Phase 1 Clinical | Mycenax Biotech Inc | Arthritis, Rheumatoid | Details | |
| Ziltivekimab | COR-001 | Phase 3 Clinical | Astrazeneca Pharmaceutical Co Ltd | Heart Failure; Anemia; Cardiovascular Diseases; Renal Insufficiency, Chronic; Inflammation; Systemic Inflammatory Response Syndrome | Details |
| Gerilimzumab | GB-224; RYI-008; ARGX-109 | Phase 1 Clinical | Argenx Se | Arthritis, Rheumatoid | Details |
This web search service is supported by Google Inc.




